▎药明康德内容团队编辑艾伯维（AbbVie）公司今日宣布，美国FDA已批准该公司与辉瑞（Pfizer）联合开发的Emblaveo（aztreonam和avibactam）上市，与甲硝唑联合使用，治疗18岁及以上复杂性腹腔内感染（cIAI）患者，包括由 ...

EMBLAVEO与甲硝唑联合使用，针对特定革兰氏阴性细菌引起的感染，包括大肠杆菌和肺炎克雷伯菌等。该批准基于该药物有限的临床安全性和有效性数据，解决了抗菌素耐药性（AMR）防控的关键需求。如果不加以解决，AMR可能在2050年前导致全球超过3,900万人死亡。凭借70.4%的强劲毛利率和稳健的现金流，AbbVie有能力支持这一重要治疗方案的商业化。投资者可通过 InvestingPro ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve ...

Find all the commercial and brand names of generic drug called Aztreonam. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

based on the results of the earlier TARGET study which showed non-inferiority for the drug compared to vancomycin plus aztreonam. If it gets a green light, it will be the first antibiotic in the ...